Skip to Main Content

Paper Details

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
J Clin Oncol
24
2022
Author NameAffiliation
Suresh Nair
Katherine S PanageasMemorial Sloan Kettering Cancer Center
  • 1 - 2

Datasets

Release 1.2